AGTR1 Is Overexpressed in Neuroendocrine Neoplasms, Regulates Secretion and May Serve as a Target for Molecular Imaging and Therapy Abstract #2984

Introduction: Peptide receptor targeting has proven to be a pivotal tool for diagnostic imaging and radioligand therapy of neuroendocrine neoplasms (NENs), which frequently express somatostatin receptors (SSTRs) on their cell surface. However, up to 30 % of NEN patients do not benefit from SSTR-based approaches, others develop a resistance.
Aim(s): Consequently, alternative cell surface targets need to be identified and characterized.
Materials and methods: Cell-based dynamic mass redistribution and calcium mobilization screening using a 998-compound library identified angiotensin II (ATII) as a strong activator of cellular signaling in NEN cells. Expression analyses of the ATII receptor type 1 (AGTR1) revealed upregulation of mRNA (RT-qPCR) and radioligand binding (autoradiography) in pancreatic (n=42) and small-intestinal (n=71) NEN tissues compared to healthy controls (n=25).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Carsten Grötzinger

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2698 Safety and Efficacy of Salvage PRRT with 177Lu-DOTA-Octreotate in Patients with Well-Differentiated Metastatic Neuroendocrine Tumours (NET)
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective therapy in patients with a somatostatin receptor-positive neuroendocrine tumour (NET). NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Nariman Ghaleb
#2744 Immediate Adverse Effects of Peptide Receptor Radionuclide Therapy (PRRT) Administration in Patients with Neuroendocrine Tumors (NETs): A Single Institution Review
Introduction: PRRT is an effective treatment for well-differentiated NET, but immediate adverse events during or shortly after administration of the treatment are not well defined.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Christopher Wee
Authors: Wee C, Dundar A, Packard A, Kendi A T, ...
#2756 Theranostic Implication of Molecular Imaging Phenotype of Well-Differentiated Lung Carcinoid by 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT
Introduction: Well-differentiated pulmonary neuroendocrine tumour, classified as typical carcinoid (TC) and atypical carcinoid (AC), is a heterogenous disease with variable clinical behaviour.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Lamiaa Zidan
Authors: Zidan L, Iravani A, Kong G, Akhurst T, ...
#2782 Clinical Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Neoplasm
Introduction: Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine neoplasms (NEN) with positive effects on both progression free survival (PFS) and overall survival (OS). Only a few previous studies have investigated the effect of a second series and hence a retreatment with PRRT.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Medical Student Michala Danielle Zacho
#2820 Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma
Introduction: Esthesioneuroblastoma (ENB) is a rare malignancy with limited therapeutic options when unresectable or metastatic. The overexpression of cell-surface somatostatin receptors in ENB is a potential molecular target making it amenable to peptide receptor radionuclide therapy (PRRT). High-level evidence supporting PRRT has been published for unresectable gastroenteropancreatic neuroendocrine tumours; however, data is limited for PRRT efficacy for ENB.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Olfat Kamel Hasan